Two institutional-based health plans in New England have announced their plans to merge.

Pharmacy benefit managers (PBMs) are only keeping less than 1% of rebates in the Medicare Part D program, passing on the rest of drug savings to plan sponsors, a report from the Government Accountability Office (GAO) found.

Unionized workers from one of the nation’s largest health systems have voted to strike against the healthcare organization in early October amid ongoing labor negotiations.


Drugmakers, wanting to develop new products informed by disease insights, are snapping up genetic profiles of hospital patients and spending hundreds of millions of dollars to get the data. But the practice is throwing into question who should control this “valuable genetic data."

When Sarah Kliff, healthcare reporter for Vox, saw an emergency department bill charging more than $600 for an encounter that ended with a band-aid, she and the media company undertook a year-long project to explore as many ED bills as possible.

Enrollment of people who are ineligible for subsidies on the individual healthcare market appears to be slowing down, according to a recent report from CMS.

Less than a year after coming aboard HHS as senior advisor to the agency’s secretary Alex Azar, for drug pricing reform, John O’Brien is stepping down from his position.

Hospital prices continue to rise and are a major contributor to overall spending in the healthcare sector, which is expected to hit $6 trillion by 2027.

Out-of-network billing in emergency departments has risen over the last few years, often leaving patients with surprise expenses even when they have insurance coverage and receive care from an in-network hospital.

After drug manufacturer Eli Lilly introduced a half-priced insulin product to the U.S. market, patients are having trouble getting the medication, the Financial Times reported.

HHS has awarded $400 million through the Health Resources and Services Administration (HRSA) to fund community health centers, rural organizations and academic institutions to develop and expand services to combat the opioid abuse crisis.

CMS has decided to cover an expensive and new therapy that uses a patient’s own genetically modified immune cells to treat cancer.